ReviewJournal of functional biomaterials2015
Intraocular Implants for the Treatment of Autoimmune Uveitis.
Review in Journal of functional biomaterials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Systematic review of clinical practice guidelines for uveitis.BMJ open ophthalmology · 2023Pooled it
- Emerging innovations in ophthalmic drug delivery for diabetic retinopathy: a translational perspective.Drug delivery and translational research · 2026Review
- Innovative triamcinolone acetonide microsuspension for Non-Invasive ocular management of inflammation.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2025Article
- Use of corticosteroids in non-infectious uveitis - expert consensus in Taiwan.Annals of medicine · 2024Review
- Pathogenesis and current therapies for non-infectious uveitis.Clinical and experimental medicine · 2023Review
- Ocular immunosuppressive microenvironment and novel drug delivery for control of uveitis.Advanced drug delivery reviews · 2023Review
- Transscleral Delivery of Dexamethasone-Loaded Microparticles Using a Dissolving Microneedle Array.Pharmaceutics · 2023Article
- Management of Diabetic Macular Edema: Guidelines from the Emirates Society of Ophthalmology.Ophthalmology and therapy · 2022Article
- Recent achievements in nano-based technologies for ocular disease diagnosis and treatment, review and update.Journal of nanobiotechnology · 2022Review
- Integrated Transcriptome Analysis of Iris Tissues in Experimental Autoimmune Uveitis.Frontiers in genetics · 2022Article
- Psoriasis beyond the skin: Ophthalmological changes (Review).Experimental and therapeutic medicine · 2021Review
- Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives.Drug delivery and translational research · 2021Review
- Polymeric Implants for the Treatment of Intraocular Eye Diseases: Trends in Biodegradable and Non-Biodegradable Materials.Pharmaceutics · 2021Review
- The Efficacy and Safety of Infliximab in Refractory Noninfectious Uveitis: A Meta-Analysis of Observational Studies.Frontiers in pharmacology · 2021Review
- Recent advances in cyclosporine drug delivery: challenges and opportunities.Drug delivery and translational research · 2019Review
- Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents.Pharmaceutics · 2019Review
- Intracameral dexamethasone injection in the treatment of cataract surgery induced inflammation: design, development, and place in therapy.Clinical ophthalmology (Auckland, N.Z.) · 2018Review
- The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future.BioMed research international · 2018Review
- Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation.Advanced healthcare materials · 2017Review
- IL-6 blockade in the management of non-infectious uveitis.Clinical rheumatology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Uveitis is the third leading cause of blindness in developed countries. Currently, the most widely used treatment of non-infectious uveitis is corticosteroids. Posterior uveitis and macular edema can be treated with intraocular injection of corticosteroids, however, this is problematic in chronic cases because of the need for repeat injections. Another option is systemic immunosuppressive therapies that have their own undesirable side effects. These systemic therapies result in a widespread suppression of the entire immune system, leaving the patient susceptible to infection. Therefore, an effective localized treatment option is preferred. With the recent advances in bioengineering, biodegradable polymers that allow for a slow sustained-release of a medication. These advances have culminated in drug delivery implants that are food and drug administration (FDA) approved for the treatment of non-infectious uveitis. In this review, we discuss the types of ocular implants available and some of the polymers used, implants used for the treatment of non-infectious uveitis, and bioengineered alternatives that are on the horizon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.